Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Accured Expenses: 2021-2025

Historic Change in Accured Expenses for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $11.0 million.

  • ARS Pharmaceuticals' Change in Accured Expenses rose 152.68% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year increase of 27090.91%. This contributed to the annual value of $16.4 million for FY2024, which is 691.72% up from last year.
  • ARS Pharmaceuticals' Change in Accured Expenses amounted to $11.0 million in Q3 2025, which was down 14.43% from $12.8 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $12.8 million during Q2 2025, with a 5-year trough of -$11.4 million in Q4 2022.
  • Over the past 3 years, ARS Pharmaceuticals' median Change in Accured Expenses value was $4.2 million (recorded in 2025), while the average stood at $3.8 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 109.67% in 2022, then skyrocketed by 1,268.75% in 2024.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Change in Accured Expenses stood at -$5.4 million in 2021, then plummeted by 109.67% to -$11.4 million in 2022, then climbed by 22.25% to -$8.9 million in 2023, then spiked by 186.51% to $7.7 million in 2024, then soared by 152.68% to $11.0 million in 2025.
  • Its Change in Accured Expenses stands at $11.0 million for Q3 2025, versus $12.8 million for Q2 2025 and $4.2 million for Q1 2025.